Mike Waring holds the Chair of Medicinal Chemistry at Newcastle University, he is Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit and Director of the EPSRC Centre for Doctoral Training in Molecular Sciences for Medicine. Previously, he was Principal Scientist in Medicinal Chemistry at AstraZeneca, UK. He is a highly experienced medicinal chemist with a track record of delivery of drug-discovery projects in oncology and cardiovascular indications, including fourteen candidate drugs for the treatment of cancer and diabetes, seven of which have thus far progressed to human trials and one has been approved by FDA (osimertinib, Tagrisso™) for the treatment of EGFR driven lung cancer. He has a keen interest in small-molecule drug discovery and the development of novel hit generation and optimization approaches. His work has been recognised by numerous international awards, including the inaugural Royal Society of Chemistry Biological and Medicinal Chemistry Lectureship (2014), the Malcolm Campbell medal (2017) and the American Chemical Society Heroes of Chemistry Prize (2018).